97 log10 IU/mL (100 mg BID) to −2.30 log10 IU/mL (700 mg BID). In study 1, the mean maximum GSK1120212 order reductions in HCV RNA were statistically greater than

placebo for all filibuvir doses evaluated. The 450 mg BID dose was investigated in TN patients (study 1) and TE patients (study 2) to assess any effect of prior treatment with pegIFN and RBV on the antiviral activity of filibuvir. When the nonresponder was excluded from the TN group, the maximum reduction in HCV RNA was not significantly different from that observed in the TE cohort in study 2, suggesting the antiviral activity of filibuvir is not affected by prior treatment status. Previously published in vitro data demonstrate that the antiviral activity of filibuvir is comparable against the two most common subtypes of HCV genotype 1 (1a and 1b; mean EC50 versus 1a = 0.081 μM; mean EC50 versus 1b = 0.033 μM).16 In the present study, similar mean maximum reductions in HCV RNA were observed for 1a and 1b isolates (−2.06 Ixazomib in vitro and −2.14 log10 IU/mL, respectively).

In addition, the frequency of virologic breakthrough was similar among patients infected with subtype 1a and 1b strains, and there was no significant difference in the frequency of appearance of position 423 mutations in patients infected with genotype 1a and 1b strains. The influence of genotype 1 subtype on maximal reduction in HCV RNA concentration was also tested in the exposure–response analysis, and it did not appear to have an effect. Therefore, these findings are consistent with in vitro data and further indicate that the antiviral activity

of filibuvir is comparable against both subtype 1a and 1b strains of HCV. Although administration of filibuvir resulted in significant decreases in HCV RNA concentrations 上海皓元 during the first 72 hours of therapy, rebound was observed in some patients. In the 15 patients receiving >100 mg BID with virologic breakthrough (defined as >0.5 log increase in HCV RNA concentration), the breakthrough occurred after day 4. Longer treatment durations resulted in an increase in the frequency of virologic breakthrough with the 450 mg BID dose: two of six patients treated with 450 mg BID in study 1 (8 days of treatment) and 9 of 10 patients treated with 450 mg BID in study 2 (10 days of treatment). In study 1, the frequency of virologic breakthrough was lowest in the 100 mg BID group, suggesting that the selective pressure exerted by this dose was insufficient to completely suppress replication of wild-type variants and enable the outgrowth of potentially less fit filibuvir-resistant variants. This observation is consistent with results from monotherapy trials with the HCV protease inhibitors boceprevir and telaprevir. In boceprevir monotherapy trials,19 patients who achieved a >2.0 log maximum reduction in HCV RNA were more likely to develop protease-inhibitor resistance mutations than those patients who achieved <2.0 log maximum reduction in HCV RNA.